KELLY LONDON: Open Payments
NPI 1376913178 · ARLINGTON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$588 in 28 payments from 10 companies in 2025. Trend: 2023 $4,105 · 2024 $1,449 · 2025 $588
Food & beverage: $588
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $188 |
| Otsuka America Pharmaceutical, Inc. | 3 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $72 |
| Lundbeck LLC | 2 | $53 |
| Bausch Health US, LLC | 3 | $49 |
| Vanda Pharmaceuticals Inc. | 2 | $43 |
| Tris Pharma Inc | 2 | $38 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| ABBVIE INC. | 1 | $28 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
Products named: CAPLYTA, REXULTI, TRINTELLIX, APLENZIN, Dyanavel XR, Auvelity, VRAYLAR, HETLIOZ.
Industry payments across VA — which companies pay providers there.
